フィブリノゲン欠乏症(Fibrinogen Deficiency):治療薬開発パイプライン動向(2015年上半期版)...市場調査レポートについてご紹介

【英文タイトル】Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H1 2015

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Fibrinogen Deficiency (Factor I Deficiency) Overview 6
Therapeutics Development 7
Pipeline Products for Fibrinogen Deficiency (Factor I Deficiency) – Overview 7
Pipeline Products for Fibrinogen Deficiency (Factor I Deficiency) – Comparative Analysis 8
Fibrinogen Deficiency (Factor I Deficiency) – Therapeutics under Development by Companies 9
Fibrinogen Deficiency (Factor I Deficiency) – Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Fibrinogen Deficiency (Factor I Deficiency) – Products under Development by Companies 12
Fibrinogen Deficiency (Factor I Deficiency) – Companies Involved in Therapeutics Development 13
Biotest AG 13
China Biologic Products, Inc. 14
Grifols, S.A. 15
Octapharma AG 16
Fibrinogen Deficiency (Factor I Deficiency) – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
fibrinogen – Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
fibrinogen concentrate (human) – Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
fibrinogen concentrate (human) – Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
fibrinogen concentrate (human) – Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
fibrinogen concentrate (human) – Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Fibrinogen Deficiency (Factor I Deficiency) – Recent Pipeline Updates 29
Fibrinogen Deficiency (Factor I Deficiency) – Discontinued Products 30
Fibrinogen Deficiency (Factor I Deficiency) – Product Development Milestones 31
Featured News & Press Releases 31
Dec 19, 2012: CSL Behring’s Fibrinogen Concentrate Given As First-Line Therapy Safely Reduces Need For Transfusion After Aortic Surgery In Phase II Study 31
Mar 23, 2012: China Biologic Receives SFDA Approval To Begin Clinical Trials For Human Fibrinogen 32
Mar 11, 2009: CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP 32
Mar 11, 2009: CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP 33
Jan 16, 2009: CSL Behring Receives FDA Approval of RiaSTAP, First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency 34
Jan 16, 2009: CSL Behring Receives FDA Approval of RiaSTAP, First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency 34
Jul 21, 2008: CSL Behring Submits BLA Requesting Approval of Human Fibrinogen Concentrate for the Treatment of Congenital Bleeding 35
Jul 21, 2008: CSL Behring Submits BLA Requesting Approval of Human Fibrinogen Concentrate for the Treatment of Congenital Bleeding 36
Jul 21, 2008: CSL Behring Submits BLA Requesting Approval Of Human Fibrinogen Concentrate For The Treatment Of Congenital Bleeding 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 37
Disclaimer 38


【レポート販売概要】

■ タイトル:フィブリノゲン欠乏症(Fibrinogen Deficiency):治療薬開発パイプライン動向(2015年上半期版)
■ 英文:Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H1 2015
■ 発行日:2015年3月11日
■ 調査会社:Global Markets Direct
■ 商品コード:GMDHC6341IDB
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。